Endothelial dysfunction is associated with graft loss in renal transplant recipients

Transplantation

Volumn 95, Issue 5, 2013, Pages 733-739

  Dahle, Dag Olav ^a   Midtvedt, Karsten ^a   Hartmann, Anders ^a   Jenssen, Trond ^a,b   Holdaas, Hallvard ^a   Mjøen, Geir ^c   Torbjorn Leivestad ^a,d   Åsberg, Anders ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Endothelial dysfunction; Kidney transplantation; Renal allograft survival

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; FOREARM; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; ADOLESCENT; AREA UNDER THE CURVE; GRAFT SURVIVAL; MIDDLE AGED; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ENDOTHELIUM, VASCULAR; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED;

MLCS; MLOWN;

EID: 84877276443     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827d6312     Document Type: Article

References (57)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154.
2. Jardine AG, Gaston RS, Fellstrom BC, et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378: 1419.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112.
4. Briet M, Burns KD. Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci (Lond) 2012; 123: 399.
5. Ross R. AtherosclerosisVan inflammatory disease. N Engl J Med 1999; 340: 115.
6. Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation 2012; 126: 753.
7. Herrmann J, Lerman A. The endotheliumVthe cardiovascular health barometer. Herz 2008; 33: 343.
8. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1.
9. Bath PM, Hassall DG, Gladwin AM, et al. Nitric oxide and prosta-cyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 1991; 11: 254.
10. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057.
11. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774.
12. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168.
13. Perticone F, Maio R, Perticone M, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010; 122: 379.
14. Nakamura T, Obata JE, Hirano M, et al. Endothelial vasomotor dysfunction in the brachial artery predicts the short-term development of early stage renal dysfunction in patients with coronary artery disease. Int J Cardiol 2011; 148: 183.
15. van GC, Lambert J, Janssen MJ, et al. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12: 14.
16. van GC, Janssen MJ, Lambert J, et al. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 1782.
17. Hausberg M, Kisters K, Kosch M, et al. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55: 1104.
18. Mercanoglu F, Oflaz H, Turkmen A, et al. Does the endothelial function change in renal transplant patients with longer duration of exposure and with higher cumulative doses of cyclosporine? Transplant Proc 2004; 36: 1361.
19. Oflaz H, Turkmen A, Turgut F, et al. Changes in endothelial function before and after renal transplantation. Transpl Int 2006; 19: 333.
20. Caglar K, Yilmaz MI, Saglam M, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007; 83: 392.
21. Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothe-lial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endo-thelial damage? Clin Transplant 2009; 23: 241.
22. Ozkurt S, Sahin G, Degirmenci NA, et al. Late effects of renal transplantation on endothelial functions and cardiac morphology. Transplant Proc 2011; 43: 2606.
23. Kas-Deelen AM, Harmsen MC, De Maar EF, et al. Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 2000; 58: 2533.
24. Mark PB, Murphy K, Mohammed AS, et al. Endothelial dysfunction in renal transplant recipients. Transplant Proc 2005; 37: 3805.
25. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010; 77: 44.
26. van Ree RM, Oterdoom LH, de Vries AP, et al. Circulating markers of endothelial dysfunction interact with proteinuria in predicting mortality in renal transplant recipients. Transplantation 2008; 86: 1713.
27. Dahle DO, Mjoen G, Oqvist B, et al. Inflammation-associated graft loss in renal transplant recipients. Nephrol Dial Transplant 2011; 26: 3756.
28. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246.
29. Asberg A, Berg KJ, Hartmann A. Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients. Microvasc Res 2000; 60: 81.
30. Mercanoglu F, Turkmen A, Kocaman O, et al. Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transplant Proc 2004; 36: 1357.
31. Oflaz H, Turkmen A, Kazancioglu R, et al. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Transplant 2003; 17: 212.
32. Ovuworie CA, Fox ER, Chow CM, et al. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation 2001; 72: 1385.
33. Joannides R, Etienne I, Iacob M, et al. Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int 2010; 23: 1135.
34. Maamoun H, Esmail E, Soliman A. Vascular endothelial function of sirolimus maintenance regimen in renal transplant recipients. Transplant Proc 2011; 43: 1616.
35. Kosch M, Hausberg M, Suwelack B. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation 2003; 76: 1516.
36. Schrama YC, van DT, Fijnheer R, et al. Cyclosporine is associated with endothelial dysfunction but not with platelet activation in renal transplantation. Neth J Med 2001; 59: 6.
37. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Forearm vasorelaxation in hypertensive renal transplant patients: the impact of withdrawal of cyclosporine. J Hypertens 1998; 16: 331.
38. Morris ST, McMurray JJ, Rodger RS, et al. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100.
39. Uchida HA, Nakamura Y, Kaihara M, et al. Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy. Nephrol Dial Transplant 2006; 21: 3475.
40. Voytovich MH, Asberg A, Hjelmesaeth J, et al. Association between insulin resistance and endothelial dysfunction in renal transplant recipients. Clin Transplant 2006; 20: 195.
41. Voytovich MH, Simonsen C, Jenssen T, et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 413.
42. Mohamed AS, Thomson J, McDonald KJ, et al. Circulating endothelial cells in renal transplant recipients. Transplant Proc 2005; 37: 2387.
43. Reriani MK, Dunlay SM, Gupta B, et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 2011; 18: 704.
44. Asberg A, Hartmann A, Fjeldsa E, et al. Atorvastatin improves endo-thelial function in renal-transplant recipients. Nephrol Dial Transplant 2001; 16: 1920.
45. Asberg A, Holdaas H, Jardine AG, et al. Fluvastatin reduces athero-genic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplant 2003; 17: 385.
46. Asberg A, Midtvedt K, Vassbotn T, et al. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. Nephrol Dial Transplant 2001; 16: 1465.
47. Baylis C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens 2012; 21: 1.
48. Asberg A, Hjelmesaeth J, Voytovich MH, et al. Endothelial function in renal transplant recipients is associated with circulating nitric oxide, ACE inhibitor use and time after transplantation. Vascular Dis Prev 2006; 3: 229.
49. Kvandal P, Stefanovska A, Veber M, et al. Regulation of human cutaneous circulation evaluated by laser Doppler flowmetry, iontophoresis, and spectral analysis: importance of nitric oxide and prostaglandines. Microvasc Res 2003; 65: 160.
50. Green DJ, Jones H, Thijssen D, et al. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 2011; 57: 363.
51. Morris ST, McMurray JJ, Spiers A, et al. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60: 1077.
52. Cottone S, Palermo A, Vaccaro F, et al. Inflammation and endothe-lial activation are linked to renal function in long-term kidney transplantation. Transpl Int 2007; 20: 82.
53. Asberg A, Holm T, Vassbotn T, et al. Nonspecific microvascular vasodilation during iontophoresis is attenuated by application of hyperosmolar saline. Microvasc Res 1999; 58: 41.
54. Brochner-Mortensen J, Rodbro P. Optimum time of blood sampling for determination of glomerular filtration rate by single-injection [51Cr]EDTA plasma clearance. Scand J Clin Lab Invest 1976; 36: 795.
55. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
56. Asberg A, Midtvedt K, Voytovich MH, et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clin Transplant 2009; 23: 511.
57. Smerud KT, Dolgos S, Olsen IC, et al. A 1-year randomized, doubleblind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant 2012; 12: 3316.